Impact of IDPN on Nutrition Markers in Patients Receiving ICHD

UnknownOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
End-stage Renal DiseaseMalnutrition; Protein
Interventions
OTHER

Intradialytic Parenteral Nutrition

"Intradialytic parenteral nutrition (IDPN) is compounded using a combination of dextrose (D70%) and amino acids (Prosol 20%, Clinisol 15%, or Plenamine 15%) with the option of adding lipids (Intralipid 20% prior to 8/2020, Clinolipid starting 8/2020 and after).~Each prescription is dosed based on patient height, weight, and other nutrition considerations including but not limited to presence of wounds, recent hospitalizations, electrolyte imbalance, etc. Adjustments to prescription are made on an as needed basis to increase or decrease goal infusion rate, adjust protein levels, and/or add or remove lipids."

Trial Locations (1)

33064

Patient Care America, Pompano Beach

Sponsors
All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Patient Care America

INDUSTRY

NCT05439174 - Impact of IDPN on Nutrition Markers in Patients Receiving ICHD | Biotech Hunter | Biotech Hunter